Summary
iShares MSCI Australia UCITS ETF (SAUSm) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has iShares MSCI Australia UCITS ETF ever had a stock split?
iShares MSCI Australia UCITS ETF Profile
| CBOE Exchange | US Country |
Overview
ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative treatments for severe allergic reactions. Established in 2015 and based in San Diego, California, the company is committed to improving the care and protection for patients experiencing life-threatening allergic reactions, also known as anaphylaxis. ARS Pharmaceuticals aims to serve a broad audience, including healthcare professionals, patients, and caregivers, by providing advanced, patient-friendly solutions for emergency situations.
Products and Services
neffy: The flagship product under development by ARS Pharmaceuticals, Inc. is neffy, a needle-free, intranasal epinephrine nasal spray designed for the emergency treatment of Type I allergic reactions, including anaphylaxis. Unlike traditional epinephrine auto-injectors, neffy offers a non-invasive, low-dose alternative that could transform the way severe allergic reactions are treated. The innovative nasal spray form aims to make administration less intimidating and more accessible in critical moments, thereby potentially increasing the likelihood of timely and effective treatment.
